Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis [Phase 1]

View source ↗

Summary

A Phase 1 pediatric study evaluating pharmacokinetics, safety, and tolerability of Upadacitinib in children with severe atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rinvoq (upadacitinib) (Upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED